Kilter Group’s Biogen BIIB Stock Holding History

Kilter Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8K	Sell	50 -2	-4%	-$383	﹤0.01%	452
2026 Q1	$9.53K	Buy	52 +3	+6%	+$553	﹤0.01%	421
2025 Q4	$8.62K	Buy	49 +14	+40%	+$2.29K	﹤0.01%	391
2025 Q3	$4.9K	Buy	35 +15	+75%	+$2.03K	﹤0.01%	465
2025 Q2	$2.51K	Buy	+20	New	+$2.49K	﹤0.01%	555

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kilter Group's BIIB Position: Q2 2026 in Review

Kilter Group reduced its Biogen (BIIB) stake by 3.8% in Q2 2026, selling an estimated $383 and leaving 50 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

Kilter Group first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Kilter Group held 50 shares of Biogen worth $10.8K as of Q2 2026.
Kilter Group sold 2 Biogen shares in Q2 2026, an estimated $383.
Biogen made up ﹤0.01% of Kilter Group's portfolio in Q2 2026, its #452 holding.
Kilter Group first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.